About Exact Sciences Corporation - Common Stock (EXAS)
Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions. With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management. Read More
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales up 16% year on year to $811.1 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 84.9% above analysts’ consensus estimates.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $811.1 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts’ estimates. Its non-GAAP profit of $0.22 per share was significantly above analysts’ consensus estimates.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current and future versions of Freenome’s blood-based, single indication, colorectal cancer (CRC) screening tests.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
